Navigation Links
Study challenges baby formula claim
Date:7/14/2011

Despite the formula being recommended in public health guidelines set out by the Australasian Society of Clinical Immunology and Allergy, the new study, published online in the Journal of Allergy and Clinical Immunology, found there was no benefit in using hypoallergenic (partially hydrolysed whey) formula to prevent allergies in high-risk infants up to seven years of age, compared to a conventional cow's milk based formula.

The trial, which is one the largest to test the effect of hypoallergenic baby formula, involved 620 infants and assessed whether using the formula decreased the risk of allergy in later life.

Infants in the study were given either hypoallergenic, cow's milk or soy formula after the cessation of breastfeeding. Allergy testing was undertaken at six, 12 and 24 months and children were followed up again at six or seven years of age.

Lead authors David Hill, a Senior Consultant Allergist at the Murdoch Childrens Research Institute and Adrian Lowe, a research fellow at the Murdoch Childrens Research Institute and the Centre for MEGA Epidemiology, the University of Melbourne said their findings did not support the recommendations that hypoallergenic formula should be used after breast feeding as a preventive strategy for infants at high risk of allergenic disease.

"In our study of high risk children, this 'hypoallergenic' formula did not show any beneficial effect, when compared with a normal cows' milk based formula, for the prevention childhood eczema, asthma or hay fever up to seven years of age," Dr Lowe said.

Dr Hill said: "Our findings do not support the role of hypoallergenic formula for the prevention of allergic disease. Families at high risk of allergy should continue to be encouraged to breast feed for the many known benefits associated with breastfeeding."


'/>"/>

Contact: Charlotte Crawford
charlotte.crawford@unimelb.edu.au
University of Melbourne
Source:Eurekalert

Page: 1

Related biology news :

1. Study explains why men are at higher risk for stomach cancer
2. First study into GM Atlantic salmon mating reveals danger of escape to wild gene pool
3. Your mother was right: Study shows good posture makes you tougher
4. Researchers study pesticide pathways into the atmosphere
5. Scleroderma study identifies roadblocks to employment
6. Study: People at risk for panic buffered from stressor by high levels of physical activity
7. UCI study points to new means of overcoming antiviral resistance in influenza
8. Owl study expands understanding of human stereovision
9. Virginia Tech Coal and Energy Center selected for study of CO2 injection into storage reservoirs
10. Large human study links phthalates, BPA and thyroid hormone levels
11. University of Houston researcher an author of multi-institutional genetic study of ovarian cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2017)... , March 2, 2017 Australian stem cell ... (ASX: CYP), has signed an agreement with the Monash ... Monash Biomedicine Discovery Institute and Department of Pharmacology at ... a further preclinical study to support the use of ... asthma.  Asthma is a chronic, long ...
(Date:2/27/2017)...   Strategic Cyber Ventures , the industry,s first ... $3.5 million investment in  Polarity , the first commercial ... DC based and is led by cybersecurity veterans ... Ron Gula , also a longtime cybersecurity veteran and ... series A round of funding. This new funding will ...
(Date:2/21/2017)... -- Der weltweite Biobanking-Sektor wird bis zum ... mit mehr als 50 Vertretern aus verschiedenen Branchen wurde aber ... diese Prognose zu realisieren. ... Zu den Schwierigkeiten für ... für die Biobank, die Implementierung Zeit sparender Technologien, ein ...
Breaking Biology News(10 mins):
(Date:3/24/2017)... March 24, 2017 On Thursday, ... session at 5,817.69, down 0.07%; the Dow Jones Industrial ... the S&P 500 closed at 2,345.96, marginally dropping 0.11%. ... closed in green, 4 sectors finished in red, and ... Stock-Callers.com has initiated reports coverage on the following Biotechnology ...
(Date:3/24/2017)... 24, 2017 Agenus Inc. (NASDAQ: AGEN), an ... and cancer vaccines, today announced participation at the following ... William Blair and Maidstone Life Sciences conference "Cancer Immunotherapy ... New York, NY . Agenus will ... at 9:40 am: Robert B. Stein , M.D., ...
(Date:3/23/2017)... ... ... Lajollacooks4u is proud to announce it has become the premiere team-building cooking event company in ... the world, such as Illumina, HP and Qualcomm, and is ranked #1 in its category ... due to its new team building format, a way for teams to not only interact ...
(Date:3/23/2017)... 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) (NW ... therapies for solid tumor cancers, today announced that ... it announced last Friday, March 17, 2017. ... investors securities totaling 28,843,692 shares, comprised of 18,843,692 ... shares of Class C Warrants pre-funded at the ...
Breaking Biology Technology: